- Home
- WXM vs APRE Comparison
WXM vs APRE Comparison
Compare WXM & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WXM
- APRE
- Stock Information
- Founded
- WXM 2009
- APRE 2006
- Country
- WXM China
- APRE United States
- Employees
- WXM N/A
- APRE N/A
- Industry
- WXM
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WXM
- APRE Health Care
- Exchange
- WXM NYSE
- APRE Nasdaq
- Market Cap
- WXM 15.3M
- APRE 13.5M
- IPO Year
- WXM 2025
- APRE 2019
- Fundamental
- Price
- WXM $2.10
- APRE $1.50
- Analyst Decision
- WXM
- APRE Strong Buy
- Analyst Count
- WXM 0
- APRE 2
- Target Price
- WXM N/A
- APRE $15.50
- AVG Volume (30 Days)
- WXM 892.8K
- APRE 29.9K
- Earning Date
- WXM 01-01-0001
- APRE 05-13-2025
- Dividend Yield
- WXM N/A
- APRE N/A
- EPS Growth
- WXM 67.61
- APRE N/A
- EPS
- WXM 0.18
- APRE N/A
- Revenue
- WXM $15,524,259.00
- APRE $1,502,581.00
- Revenue This Year
- WXM N/A
- APRE N/A
- Revenue Next Year
- WXM N/A
- APRE N/A
- P/E Ratio
- WXM $12.00
- APRE N/A
- Revenue Growth
- WXM 10.86
- APRE 157.63
- 52 Week Low
- WXM $1.52
- APRE $1.48
- 52 Week High
- WXM $7.99
- APRE $5.90
- Technical
- Relative Strength Index (RSI)
- WXM N/A
- APRE 22.57
- Support Level
- WXM N/A
- APRE $1.52
- Resistance Level
- WXM N/A
- APRE $1.66
- Average True Range (ATR)
- WXM 0.00
- APRE 0.14
- MACD
- WXM 0.00
- APRE 0.01
- Stochastic Oscillator
- WXM 0.00
- APRE 2.44
About WXM WF INTERNATIONAL LIMITED
WF International Ltd is engaged in the provision of supply, installation, fitting-out and maintenance services for HVAC system and floor heating systems. It provides the supply, installation and fitting-out services for HVAC systems for large-scaled commercial projects consisting of offices, hotels, manufactures, airports and hospitals, such as the International Finance Square HVAC projects across China, Chengdu Vanke Charm City, Chengdu Raffles Plaza, Chengdu Yinshi Plaza, Chengdu Metro No. Ten Line, and Panzhihua Jinhai Hotel.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.